Abbvie
AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology.
The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs.
Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
+12 vs industry average
Abbvie’s score of 50 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Abbvie?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Abbvie's reported carbon emissions
In 2025, AbbVie reported total greenhouse gas emissions of approximately 380,850,000 kg CO2e, comprising 304,649,000 kg CO2e from Scope 1 and 76,201,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2021 as the baseline year. This commitment aligns with the Science Based Targets initiative (SBTi) and includes a goal to increase the sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. Additionally, AbbVie aims for 79.1% of its suppliers to have science-based targets by 2027. Over recent years, AbbVie has demonstrated a commitment to reducing its carbon footprint, with a notable reduction of approximately 12.4% in Scope 1 emissions from 342,607,000 kg CO2e in 2022 to 328,259,000 kg CO2e in 2023. The company is also targeting a 25% reduction in absolute emissions by 2025 from a 2015 baseline. AbbVie is headquartered in the United States and is actively working towards achieving net zero emissions by 2050, reflecting its dedication to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Abbvie’s Climate Goals (2030 & 2050)
4 goals2035
50% reduction in Scope 2
Reduce absolute carbon emissions (Scope 1 and Scope 2 – market-based) vs. 2015 baseline1 -50%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Abbvie
Frequently asked questions
Common questions about Abbvie’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project